Measurable Residual Disease: The Future of Multiple Myeloma Assessment?
Advances in technology for detecting measurable residual disease (MRD) are also raising questions regarding the role of MRD in managing multiple myeloma.
Lauren Dembeck, PhD
Contributing Writer https://www.cancertherapyadvisor.com
Lauren Dembeck is a freelance science and medical writer and a contributing author for the Haymarket Medical Network. She holds a BS in biology and a BA in foreign languages from West Virginia University and a PhD in genetics from North Carolina State University. Prior to freelance writing, Lauren was a postdoctoral researcher at the Okinawa Institute of Science and Technology in Japan, where she studied developmental neurobiology. You can find more of her writing at https://laurendembeck.com/
